HAPTOGLOBIN DERIVATIVE FOR TREATMENT OF SEPSIS AND ACETAMINOPHEN-INDUCED LIVER DAMAGE
Methods for treating sepsis of acetaminophen-induced liver damage in a subject sing a haptoglobin derivative are provided. Compositions containing a haptoglobin derivative for treating sepsis of acetaminophen-induced liver damage are provided.
1 . A method of treating sepsis in a subject, comprising administering to the subject an amount of composition comprising a peptide having SEQ ID NO:1 but not comprising SEQ ID NO:2, effective to treat sepsis in a subject.
2 . A method of reducing the likelihood of mortality from sepsis in a subject having the sepsis, comprising administering to the subject an amount of composition comprising a peptide having SEQ ID NO:1 but not comprising SEQ ID NO:2, effective reduce the likelihood of mortality of a subject from sepsis.
3 . A method of inhibiting HMGB1-induced TNF release from a macrophage in a subject, comprising administering to the subject an amount of composition comprising a peptide having SEQ ID NO:1 but not comprising SEQ ID NO:2, effective to inhibit HMGB1-induced TNF release from a macrophage in a subject.
4 . A method of treating acetaminophen-induced liver damage in a subject, comprising administering to the subject an amount of composition comprising a peptide having SEQ ID NO:1 but not comprising SEQ ID NO:2, effective to treat acetaminophen-induced liver damage in a subject.
5 . The method of claim 1 , wherein the composition is administered intravenously.
6 . The method of claim 1 , wherein the peptide is recombinantly produced.
7 . The method of claim 1 , wherein the peptide is fused to a molecule that increases plasma-half life of the peptide.
8 . The method of claim 1 , wherein the peptide is fused to an XTEN molecule, a PEG molecule, or an albumin molecule.
9 . The method of claim 1 , wherein the peptide consists of L-amino acids.
10 . The method of claim 1 , wherein the peptide comprises L-amino acids and D-amino acids.
11 . The method of claim 1 , wherein the peptide consists of D-amino acids.
12 . The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
13 . A composition comprising a peptide having SEQ ID NO:1 but not comprising SEQ ID NO:2, wherein the peptide is fused to a molecule that increases plasma-half life of the peptide.
14 . The composition of claim 13 , wherein the peptide is fused to an XTEN molecule, a PEG molecule, or an albumin molecule.
15 . The composition of claim 13 , wherein the peptide consists of L-amino acids.
16 . The composition of claim 13 , wherein the peptide comprises L-amino acids and D-amino acids.
17 . The composition of claim 13 , wherein the peptide consists of D-amino acids.
18 . The composition of claim 13 , wherein the composition comprises a pharmaceutically acceptable carrier.